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Background—Tissue edema and endothelial barrier dysfunction as observed in sepsis and acute lung injury carry high
morbidity and mortality, but currently lack specific therapy. In a recent case report, we described fast resolution of
pulmonary edema on treatment with the tyrosine kinase inhibitor imatinib through an unknown mechanism. Here, we
explored the effect of imatinib on endothelial barrier dysfunction and edema formation.
Methods and Results—We evaluated the effect of imatinib on endothelial barrier function in vitro and in vivo. In human
macro- and microvascular endothelial monolayers, imatinib attenuated endothelial barrier dysfunction induced by
thrombin and histamine. Small interfering RNA knock-downs of the imatinib-sensitive kinases revealed that imatinib
attenuates endothelial barrier dysfunction via inhibition of Abl-related gene kinase (Arg/Abl2), a previously unknown
mediator of endothelial barrier dysfunction. Indeed, Arg was activated by endothelial stimulation with thrombin,
histamine, and vascular endothelial growth factor. Imatinib limited Arg-mediated endothelial barrier dysfunction by
enhancing Rac1 activity and enforcing adhesion of endothelial cells to the extracellular matrix. Using mouse models of
vascular leakage as proof-of-concept, we found that pretreatment with imatinib protected against vascular endothelial
growth factor–induced vascular leakage in the skin, and effectively prevented edema formation in the lungs. In a murine
model of sepsis, imatinib treatment (6 hours and 18 hours after induction of sepsis) attenuated vascular leakage in the
kidneys and the lungs (24 hours after induction of sepsis).
Conclusions—Thus, imatinib prevents endothelial barrier dysfunction and edema formation via inhibition of Arg. These
findings identify imatinib as a promising approach to permeability edema and indicate Arg as novel target for edema
treatment. (Circulation. 2012;126:2728-2738.)
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The endothelium tightly controls the exchange of fluidfrom the circulation to the surrounding tissues. Dysfunc-
tion of this barrier leads to uncontrolled fluid extravasation
and edema,1–3 and characterizes life-threatening conditions
like sepsis1 and acute lung injury.4 Despite high mortality
rates—up to 50% in sepsis—no treatment is currently avail-
able for endothelial barrier dysfunction and edema.1 How-
ever, in a recent case report we described fast resolution of
pulmonary edema on treatment with imatinib.5
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Imatinib is a small molecule inhibitor, blocking the ATP-
ase activity of the kinases c-Abl, Abl-related gene (Arg/
Abl2), platelet-derived growth factor receptor (PDGFR),
c-KIT, and discoid domain receptor-1.6 Thus far, imatinib has
found its major application in the treatment of Brc-Abl
positive chronic myeloid leukemia and gastro-intestinal stro-
mal tumors,6 whereas nonmalignant proliferative disorders
like lung fibrosis7 and pulmonary hypertension8 may form
future applications of imatinib. Although designed as a smart
drug specifically targeting overactive kinases, imatinib is
associated with several side effects. Long-term treatment with
imatinib may lead to cardiac failure by inducing cardiomyo-
cyte apoptosis,9 and, of note, long-term treatment with
imatinib was associated with subcutaneous edema.10
In the light of these studies the association of imatinib
treatment with resolution of edema is surprising. Yet, increas-
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ing evidence indicates that imatinib may protect against
edema.11–13 A second case report revealed clinical improve-
ment of acute lung injury on initiation of imatinib,11 whereas
two experimental studies demonstrated that imatinib protects
against brain edema after stroke.12,13 The mechanism by
which imatinib may protect against edema remains largely
unclear. The protective effect of imatinib on brain edema was
mainly attributed to PDGFR- inhibition on perivascular
astrocytes,12,13 which is unlikely to explain the protective
effects of imatinib observed in pulmonary edema. Otherwise,
the descriptive character of mentioned case reports5,11 limited
mechanistic interpretation, although an effect of imatinib on
endothelial barrier function was suggested.5
Little is known about the direct effects of imatinib on the
endothelial barrier as main regulator of fluid exchange. In the
current study we hypothesized that imatinib reduces edema
formation via direct preservation of endothelial barrier integ-
rity. Using in vitro and in vivo models of endothelial barrier
dysfunction, we show that imatinib effectively protects
against endothelial barrier dysfunction and edema formation.
Methods
Endothelial Barrier Function Assays
Endothelial barrier function was evaluated with horseradish peroxi-
dase (HRP) passage and electric cell-substrate impedance sensing.
For measurement of HRP passage, confluent cells were seeded in 1:1
density on 0.33 cm2 Costar polycarbonate filters, pore-size 3.0 m
(Corning, Lowell, MA), and grown to confluence in 5 days. For
pretreatment, pharmacological inhibitors or vector were dissolved in
M199 (Biowhittaker/Lonza, Verviers, Belgium) supplemented with
1% human serum albumin (HSA; Sanquin Blood Supply, Amster-
dam, The Netherlands), and added to the upper compartment of the
filters during 60 minutes. For stimulation, pretreatment medium was
changed for 1%HSA/M199 containing designated inhibitors, HRP 5
g/mL (Sigma Aldrich, Zwijndrecht, the Netherlands) and thrombin
1 U/mL (Sigma Aldrich). 1%HSA/M199 was added to the lower
compartment. At indicated time points, samples were taken from the
lower compartment. The HRP concentration was detected by mea-
suring chemoluminiscence after addition of TMB/E (Upstate/Milli-
pore, Temecula, CA).
For electric cell-substrate impedance sensing measurements, cells
were seeded in 1:1 density on gelatin-coated electric cell-substrate
impedance sensing arrays, each containing 8 wells with 10 gold
electrodes per well (Applied Biophysics, Troy, NY). Culture me-
dium was renewed 24 hours after seeding, and experiments were
performed 48 hours after seeding. For pretreatment, pharmacological
inhibitors or vector were dissolved in 1%HSA/M199. After 90
minutes of pretreatment, thrombin or histamine were added directly
to the wells for final concentrations of 1 U/mL or 105 mol/L,
respectively. During stimulation, resistance was measured at multi-
ple frequencies to allow for calculation of resistance attributable to
cell–cell adhesion (Rb) and to cell–matrix interaction (Alpha).14,15
Evans Blue/Albumin Extravasation in Mouse Skin
Extravasation of albumin was visualized in the Miles assay by
extravasation of Evans blue.3 Male Balb/cByJ mice (Charles River,
25–30 g) were anesthetized with fentanyl, midazolam, and
acepromazine. Anesthetized mice were treated with imatinib mesy-
late (20 mg/kg in PBS, intraperitoneally) or vector. Five minutes
later 150 L Evans Blue (Merck, Darmstadt, Germany, 0.5% in
PBS) was administered via the tail vein and left circulating for 30
minutes. Subsequently, vascular endothelial growth factor (VEGF)
was injected intradermally in the back skin. Mice were euthanized
after 30 minutes of VEGF stimulation, and circular skin patches (ø
8 mm) from the injection sites were incubated in formamide for 24
hours. Extracted Evans Blue and hemoglobin was measured spec-
trophotometrically at 610 and 450 nm, respectively. The Evans
Blue/hemoglobin ratio is given.
Edema Formation in the Isolated Perfused
Mouse Lung
Pulmonary vascular permeability for fluid was analyzed as
described earlier.16 In brief, mixed C57/Bl6 mice (Jackson Lab-
oratories, 25–30 g) were anesthetized with ketamine and xylazine.
Anesthetized mice were treated with imatinib mesylate (50 mg/kg in
PBS, intraperitoneally) or vector. Thirty minutes after imatinib
administration, thrombin receptor-1 activating peptide (TRAP,
TFLLRN, 5 mg/kg) was administered via the jugular vein and left
circulating for 30 minutes. After 30 minutes, mice were intubated by
tracheostomy, and heart and lungs were removed en bloc. The
pulmonary artery and left atrium were cannulated, and the heart and
lungs were positioned on a weighing scale. The lungs were ventilated
and perfused with RPMI1640/HEPES buffer (2 mL/min). After 20
minutes of equilibration the lung weight was zeroed, and the outflow
pressure was increased with 8 cm H2O for 20 minutes while lung
weight was monitored. The weight increase of the lungs over time
yields the Kfc (mL/min/cmH2O/g) reflecting pulmonary vascular
permeability for fluid.
Cecal Ligation and Puncture
Male C57/BL6J mice (Harlan, 25–30 g) were anesthetized with
isoflurane (4% vol/vol in air during induction and 1.5%–2% main-
tenance) and oxygen 0.5 L/min. The abdominal cavity was opened
with a 1-cm cut over the medial line, and the cecum was positioned
outside the abdominal cavity. For cecal ligation and puncture (CLP),
75% of the cecum was ligated with 5-0 vicryl (Johnson-Johnson Intl,
New Brunswick, NJ) and perforated through-and-through with a
21-G needle.17 After extrusion of a column of 1 mm feces, the cecum
was repositioned in the abdominal cavity. For sham surgery, the
cecum was only positioned outside the abdominal cavity and
repositioned. The abdominal cavity was closed with a continuous
ligature through the abdominal muscle wall and single ligatures in
the skin. After surgery, mice received fluid resuscitation and anal-
gesia. At t6 hours and t18 hours after surgery, mice were treated
with imatinib mesylate (50 mg/kg in PBS) or vector by subcutaneous
injection in the neck. At t23 hours, 100 L Evans Blue (1% in
PBS) was administered via the tail vein and left circulating for 1
hour. At 24 hours after surgery, mice were anesthetized with
fentanyl, midazolam, and acepromazine, and euthanized by with-
drawal of 0.5 to 1 mL blood from the heart. Whole blood was
collected in heparinized tubes, centrifuged for 10 minutes at 1800g
and 4°C. Plasma (75 L) was added to 150 L formamide for
determination of the Evans Blue concentration in the plasma. The
kidneys, liver, and lungs were collected and thoroughly washed in
saline. Evans Blue was extracted from organ tissue by incubating
organs in 300 L (kidneys and lungs) or 500 L (liver lobe)
formamide at 55°C. After 48 hours the organs were removed; the
remaining formamide was centrifuged (13 500 rpm for 5 minutes)
and analyzed spectrophotometrically at 610 nm (Evans Blue) and
740 nm (overlap of hemoglobin in the Evans Blue range). The
corrected Evans Blue absorbance was calculated by the following
formula: OD610[1.426OD7400.03].18 After Evans Blue mea-
surement, organs were washed to remove the formamide and air
dried at 90°C to determine dry weight. Vascular leakage is presented
as the amount of organ Evans Blue absorbance, corrected for organ
dry weight and plasma Evans Blue absorbance.
All animal experiments were performed with approval of the
Animal Ethical Committees of the VU University Medical Center or
the University of Illinois at Chicago.
Statistical Analyses
Data are reported as meanstandard error of the mean (SEM). n
refers to the number of independent experiments with cells from
different donors, unless stated otherwise. With the hypothesis that
imatinib decreases endothelial hyperpermeability via an effect on
Arg activation, the effect of interventions (imatinib, siRNAs) on
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endothelial barrier function and activation of specific signaling
molecules was tested for statistical significance. For comparison of 2
conditions a Student t test was used, for comparison of 2
conditions a 1-way ANOVA with Tukey post hoc test or a repeated
measures ANOVA with Bonferroni post hoc test was used when
appropriate, as indicated in the figure legends. P values 0.05 were
considered statistically significant.
Additional methods and materials used for this study can be found
in the online-only Data Supplement.
Results
Imatinib Attenuates Disruption of the Endothelial
Barrier by Thrombin and Histamine
The direct effect of imatinib on endothelial barrier function
was evaluated in isolated human endothelial cell monolayers
under basal and stimulated conditions. Short-term treatment
of human lung microvascular endothelial cells and human
umbilical vein endothelial cells (HUVECs) with imatinib did
not affect endothelial barrier function under basal conditions
(Figure 1A and 1D). However, imatinib dose-dependently
attenuated endothelial barrier disruption by thrombin with an
optimal dose at 10 mol/L in HUVECs (Figure I in the
online-only Data Supplement). Imatinib 10 mol/L effec-
tively protected against endothelial barrier dysfunction,
shown by a 46% and 44% reduction in thrombin-induced
macromolecule passage (Figure 1A and 1D) and a 9% and
28% attenuation of the thrombin-induced decrease in endo-
thelial electric resistance (Figure 1B and 1E). Immunostain-
ing of the cell–cell junctional proteins -catenin and VE-
cadherin revealed that imatinib prevents the formation of
intercellular gaps after thrombin stimulation. (Figure 1C and
Figure II in the online-only Data Supplement). Imatinib also
attenuated endothelial barrier dysfunction in microvascular
endothelial cells isolated from human skin (Figure III in the
online-only Data Supplement) and endothelial barrier dys-
function induced by histamine (Figure 1F). Together these
data show that imatinib effectively protects against endothe-
Figure 1. Imatinib protects against endothelial barrier dysfunction. A, Macromolecule passage (horseradish peroxidase, HRP) over
human pulmonary microvascular endothelial cell (HPMVEC) monolayers during thrombin (1U/mL) stimulation. *P0.05 compared with
Vector  thrombin in Bonferroni post hoc test of repeated measures ANOVA (n3 donors). B, Absolute endothelial electric resistance
of HPMVEC monolayers during thrombin stimulation. Inset, Quantification of the thrombin response by calculating the maximal drop in
resistance (%). *P0.05 (n9 experiments with cells from 3 donors). C, Immunofluorescence imaging of the adherens junction protein
-catenin (green) and the nuclei (blue) in human umbilical vein endothelial cells (HUVECs). Arrows indicate presence of intercellular
gaps. Scale bars, 10 m. Representative images of n3 experiments. D, Effects of imatinib on endothelial barrier function under basal
and thrombin stimulated conditions as measured by macromolecule passage over HUVEC monolayers. *P0.05, ***P0.001 compared
with Vector  thrombin in Bonferroni post hoc test of repeated measures ANOVA (n4 donors). E, Absolute endothelial resistance of
confluent HUVEC monolayers during thrombin stimulation. Inset, The thrombin response (% decrease in resistance) in imatinib- versus
vector-pretreated cells. **P0.01 (n5 donors). F, Absolute endothelial resistance of confluent HUVECs during stimulation with hista-
mine (105 mol/L). Inset, Effects of imatinib on the histamine response (% decrease in resistance). *P0.05 (n4 donors).
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lial barrier dysfunction, independent of endothelial cell type
or barrier-disruptive agent.
Imatinib Exerts its Protective Effect via Inhibition
of the Tyrosine Kinase Abl-Related Gene (Arg)
To elucidate the kinase through which imatinib exerts its
protective effect on endothelial barrier function, we per-
formed siRNA knock-downs of the known imatinib-sensitive
tyrosine kinases (c-Abl, Arg, PDGFR, c-KIT, discoid domain
receptor-1) and evaluated the effects on thrombin-induced
endothelial barrier dysfunction. Knock-down of PDGFR-/,
c-Abl, c-KIT, or discoid domain receptor-1 did not affect the
thrombin response (Figure IVA–IVH in the online-only Data
Supplement). In contrast, knock-down of Arg attenuated the
thrombin-induced increase in macromolecule passage (Figure
2A) and decrease in endothelial resistance (Figure 2B). Knock-
down of Arg and treatment with imatinib similarly attenuated the
thrombin response, whereas imatinib had no additive protective
effect in Arg-depleted cells (Figure 2C), indicating that imatinib
exerts its protective effects predominantly via inhibition of Arg.
To establish whether Arg is activated during endothelial barrier
dysfunction, we measured CrkL phosphorylation at Tyr207 (an
exclusive target for c-Abl and Arg19) in c-Abl–depleted cells.
Thrombin induced robust CrkL phosphorylation in c-Abl–de-
pleted cells, which could be prevented by imatinib or combined
c-Abl/Arg knock-down (Figure 2D and 2E). Arg was also
activated on stimulation with the barrier-disruptive agents VEGF
and histamine (Figure 2F). These findings identify Arg as a
novel mediator of endothelial barrier dysfunction. Arg-mediated
endothelial barrier dysfunction can be effectively inhibited with
imatinib.
Arg Inhibition Prevents Loss of Cell–Matrix
Interaction During Endothelial Stimulation
Our next step was to analyze the effect of imatinib on
processes regulating endothelial barrier function. A func-
tional endothelial barrier is characterized by low actomyosin
tension and stable cell–cell junctions. During endothelial
barrier dysfunction increased actomyosin contraction and
disruption of cell–cell junctions result in gap formation.1,2
Tight adhesion of endothelial cells to the subcellular matrix
counteracts cell retraction, and as such limits junction disrup-
tion and gap formation.2,20,21 Imatinib did not affect RhoA/
Rho kinase activity or calcium-dependent signaling (Figure
3), as main determinants of actomyosin contraction. More-
over, imatinib did not visibly change the morphology of actin
fibers (data not shown). Resolving the endothelial resistance
measurements into separate components reflecting cell–cell
contact and cell–matrix interaction14,15 displayed that Arg
inhibition with siRNA or imatinib predominantly attenuated
the loss of cell–matrix interaction during thrombin stimula-
tion (Figure 4A and 4B and Figure V in the online-only Data
Supplement). Using immunofluorescence and live-cell imag-
ing of the focal adhesion marker paxillin we indeed observed
Figure 2. Imatinib protects against endothelial barrier dysfunction through inhibition of Abl-related gene (Arg). A, Arg knockdown atten-
uates thrombin-induced macromolecule passage. Macromolecule (horseradish peroxidase, HRP) passage over wild-type vs Arg-
depleted human umbilical vein endothelial cells (HUVECs) under basal and stimulated (thrombin 1 U/mL) conditions. *P0.05, **P0.01
compared with scRNA  thrombin in Bonferroni post hoc test of repeated measures ANOVA (n4). B, Absolute endothelial electric
resistance of wild-type vs Arg-depleted HUVECs during thrombin (1 U/mL) stimulation. Inset, The thrombin response (% decrease in
resistance) in wild-type vs Arg-depleted cells. **P0.01 (n4). C, The thrombin response (% decrease in resistance) in wild-type or
Arg-depleted HUVECs, pretreated with imatinib or vector. NSnon significant in Tukey post hoc test of 1-way ANOVA (n5). D, West-
ern Blot analysis of CrkL phosphorylation at Tyr207 during thrombin stimulation. Upper, Thrombin-induced Tyr207 CrkL phosphoryla-
tion in c-Abl depleted HUVECs. Lower, Effects of imatinib on thrombin-induced Tyr207 CrkL phosphorylation. E, Thrombin-induced
Tyr207 CrkL phosphorylation in HUVECs transfected with scRNA or siRNA against c-Abl, Arg or c-Abl, and Arg. F, Western Blot analy-
sis of Tyr207CrkL phosphorylation in c-Abl–depleted endothelial cells. Upper, Tyr207 CrkL phosphorylation in c-Abl depleted HUVECs
stimulated with VEGF 10 ng/mL. Lower, Tyr207 CrkL phosphorylation in c-Abl–depleted HUVECs stimulated with histamine 105 mol/L.
scRNA indicates scrambled RNA; siRNA, small interfering RNA.
Aman et al Imatinib Protects Against Vascular Leak 2731
that imatinib enhanced the formation of focal adhesions, in
particular at the cell periphery (Figure 4C and 4D and Figure
VI and Movie I in the online-only Data Supplement). Fur-
thermore, the activity of Rac1—a GTPase known to reinforce
both cell–matrix interaction21 and cell–cell junctions1,2—was
enhanced by imatinib during thrombin stimulation (Figure
4E). Together, these data indicate that imatinib limits Arg-
mediated endothelial barrier dysfunction by enhancing Rac1
activity and by enforcing adhesion of endothelial margin
areas to the extracellular matrix.
Figure 3. The protective effect of imatinib does not involve the RhoA/Rho kinase pathway and calcium-dependent signaling. A, RhoA
activity on thrombin (1 U/mL) stimulation in human umbilical vein endothelial cells (HUVECs). Imatinib did not affect thrombin-induced
RhoA activation. *P0.05, ***P0.001 compared with 0 minutes, NSnon significant in Bonferroni post hoc test of repeated measures
ANOVA (n3–4). B, The thrombin response (% decrease in resistance) in HUVECs treated with imatinib, the Rho kinase inhibitor
Y27632, or the combination. Imatinib had an additive effect to Y27632, indicating that imatinib exerts its protective effect independent
of Rho kinase activity. *P0.05, **P0.01 in Tukey post hoc test of 1-way ANOVA (n3). C, The thrombin response (% decrease in
resistance) in HUVECs treated with imatinib, the intracellular calcium chelator BAPTA-AM, or the combination. Imatinib had an additive
effect to BAPTA-AM, indicating that imatinib exerts its protective effect independent of calcium-dependent pathways. *P0.05,
**P0.01 in Tukey post hoc test of 1-way ANOVA (n3). RhoA indicates Ras homolog family member A; and BAPTA-AM, 1,2-bis-(o-
Aminophenoxy)-ethane-N,N,N’,N’-tetraacetic acid, tetraacetoxymethyl ester.
Figure 4. Abl-related gene (Arg) inhibition improves cell–matrix interaction during thrombin stimulation. A, Absolute endothelial electric
resistance attributable to cell–matrix interaction (Alpha) of wild-type vs Arg-depleted human umbilical vein endothelial cells (HUVECs)
during thrombin (1 U/mL) stimulation (n4). B, The effects of thrombin on cell–matrix interaction (%) of wild-type vs Arg-depleted
HUVECs. *P0.05 (n4). C, Immunofluorescence staining of pY118 paxillin (green) and VE-cadherin (red) for visualization of focal
adhesion (FA) formation. Scale bars, 10 m. Representative images of n3 to 4 experiments. D, Quantification of the number of FAs
during thrombin stimulation as observed during pY118 paxillin staining. *P0.05, **P0.01 in Bonferroni post hoc test of repeated
measures ANOVA (n3–4). E, Normalized Rac1 activity in HUVECs during thrombin stimulation. ***P0.001 in Bonferroni post hoc test
of repeated measures ANOVA (n4). scRNA indicates scrambled RNA; siRNA, small interfering RNA.
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Effect of Imatinib-Sensitive Tyrosine Kinases on
Basal Barrier Function
Although imatinib had no effect on basal barrier function
(Figure 1A and 1D), we observed that inhibition of individual
imatinib-sensitive kinases did change basal endothelial bar-
rier function. Under nonstimulated conditions PDGFR- and
c-KIT–depleted endothelial monolayers displayed improved
barrier function, whereas c-Abl depletion reduced barrier
function (Figure 5A). The finding that simultaneous inhibi-
tion of all these kinases (cq, by imatinib) has no effect on
basal barrier function, suggests that the barrier-impairing
effect of c-Abl inhibition is balanced by the beneficial effect
of PDGFR and c-KIT inhibition, rendering a net zero effect
on basal endothelial barrier function. To test this, we treated
endothelial cell monolayers with Tyrphostin AG1296, a
selective inhibitor of PDGFR and c-KIT. Tyrphostin AG1296
enhanced endothelial resistance up to 35% (Figure 5B). These
data indicate that under basal conditions c-Abl inhibition
opposes the barrier enforcing effects of Arg/PDGFR/c-KIT
inhibition, whereas thrombin-induced endothelial barrier dys-
function was only influenced by Arg.
Imatinib Protects Against Vascular Leakage and
Pulmonary Edema Formation In Vivo
To establish the protective effect of imatinib on endothelial
barrier function in vivo, we tested imatinib in mouse models
of vascular leakage and pulmonary edema. VEGF-induced
vascular leakage of albumin was measured by intravenous
injection of Evans Blue, followed by injection of VEGF in the
skin.3 Vascular leakage was compared between mice pre-
treated with imatinib and mice pretreated with vector. Ima-
tinib treatment (20 mg/kg) attenuated VEGF-induced extrav-
asation of Evans Blue in the skin by 39% to 55% (Figure 6A
and 6B). Next, we measured the effect of imatinib on
pulmonary edema formation. Acute pulmonary edema was
induced in vivo by intravenous injection of thrombin-receptor
activating peptide in mice pretreated with imatinib or vector.
Ex vivo, the weight gain of isolated perfused lungs was
measured, reflecting the pulmonary vascular permeability for
fluid (Kfc).16 Imatinib treatment (50 mg/kg) reduced pulmo-
nary edema formation, shown by 66% reduction of Kfc
(Figure 6C). Thus, imatinib effectively prevents vascular
leakage and edema formation in vivo.
To exclude the possibility that the attenuation of vascular
leakage resulted from a smaller hydrostatic pressure differ-
ence or a decrease in microvascular perfusion, we measured
the effect of imatinib on these parameters in an experimental
set-up similar to the Miles assay and the Kfc measurements.
First, systemic blood pressure was measured using radio
telemetry. Blood pressure was monitored before and after
administration of imatinib (Figure VIIA in the online-only
Data Supplement). Comparing mean arterial pressure 5 min-
utes before and 30 minutes after administration of imatinib,
no effect of imatinib on mean arterial pressure was observed
(Figure 6D; Figure VIIA in the online-only Data Supple-
ment). Subsequently, the effect of imatinib on microvascular
perfusion was evaluated in skin and muscle by contrast-
enhanced ultrasonography. Comparing microvascular blood
volume (as measure of microvascular perfusion) before and
after administration of imatinib, we found that imatinib did
not decrease microvascular perfusion in skin (Figure 6E and
6F; Figure VIIB in the online-only Data Supplement) or
muscle (Figure VIIC–VIIE in the online-only Data Supple-
ment), but rather caused a nonsignificant increase.
Together, these experiments indicate that the protective effect
of imatinib on vascular leakage cannot be explained by smaller
hydrostatic pressure differences or decreased microvascular
perfusion. As proof-of-concept these data therefore support the
hypothesis that imatinib prevents vascular leakage through a
direct protective effect on the endothelial barrier.
Imatinib Treatment Attenuates Vascular Leakage
During Sepsis
To evaluate the effect of imatinib in a clinically relevant
disease model, sepsis was induced by CLP,17 and mice were
treated with imatinib or vector 6 hours and 18 hours after
induction of sepsis (Figure 7A). For evaluation of vascular
leakage, Evans Blue was administered intravenously 23 hours
after induction of sepsis, and organs were harvested 1 hour
after Evans Blue administration. Septic mice treated with
vector showed a 2- to 3-fold increase in Evans Blue in the
kidneys, which was attenuated by 50% in septic mice treated
with imatinib 50 mg/kg (Figure 7B). A similar trend was
Figure 5. The effect of individual inhibition of the
imatinib-sensitive kinases on basal endothelial bar-
rier function. A, Basal endothelial electric resis-
tance in human umbilical vein endothelial cells
(HUVECs; % of wild type, WT) treated with siRNA
against the imatinib-sensitive kinases. KD indi-
cates knock-down. *P0.05, ***P0.001 com-
pared with WT in paired t test (n3–5). B, The
effects of combined platelet-derived growth factor
receptor (PDGFR) and c-KIT inhibition on endothe-
lial barrier function. Basal endothelial resistance
(% of Vector) of HUVECs treated with the PDGFR/
c-KIT inhibitor Tyrphostin AG1296. **P0.01 in
1-way ANOVA with Tukey post hoc test (n3).
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observed for the liver, although post hoc analyses did not show
a statistical difference between vector- and imatinib-treated mice
(Figure 7C). In the lungs, a slight increase of Evans Blue was
observed in septic mice treated with vector. This increase was
not significant, mainly because not all mice developed vascular
leakage in the lungs (Figure 7D). Yet, the number of mice that
developed pulmonary vascular leakage on sepsis was signifi-
cantly higher in vector-treated mice than in imatinib-treated mice
(0/5 in the sham group versus 3/6 in the CLPvector group
versus 0/5 in the CLPimatinib group; P0.05 in a 2 test).
This animal study demonstrates that imatinib attenuates vascular
leakage in a clinically relevant disease model and indicates that
imatinib is also effective when imatinib treatment is initiated
after induction of disease.
Discussion
Here we show that treatment with imatinib is an effective
therapeutic approach to endothelial barrier dysfunction and
vascular leakage. Imatinib attenuated endothelial barrier dys-
function in human endothelial cells isolated from multiple
origins and stimulated with a variety of barrier-disruptive
agents. Specifically, we found that imatinib exerts its protec-
tive effects via inhibition of Arg, a thus far unknown mediator
of endothelial barrier dysfunction. Imatinib limited Arg-
mediated endothelial barrier dysfunction by enhancing Rac1
activity and enforcing adhesion of endothelial cells to the
extracellular matrix. The barrier-protective effect of imatinib
was established in in vivo models of vascular leakage and
pulmonary edema.
Effect of Imatinib on Endothelial Barrier Function
Our finding that short-term treatment with imatinib protects
against endothelial barrier dysfunction and edema formation
provides first mechanistic insight regarding previous case
reports on patients in whom initiation of imatinib treatment
was followed by fast resolution of pulmonary edema.5,11
Figure 6. Effects of imatinib on vascular leakage and edema formation in vivo. A, Vascular endothelial growth factor (VEGF)–induced
vascular leakage of albumin-bound Evans Blue in the back skin of Balb/cJ mice pretreated with saline or imatinib (20 mg/kg). Scale
bar, 5 mm. B, Quantification of formamide-extracted Evans Blue by spectrophotometrically (610 nm), corrected for hemoglobin (450
nm). NS indicates nonsignificant; *P0.05 (n6 or 7 mice per group). C, Permeability of the lung vasculature (Kfc) on thrombin receptor
activation in C57/Bl6J mice pretreated with saline or imatinib (50 mg/kg). TRAP indicates thrombin receptor activating peptide.
**P0.01 (n3 or 4 mice per group). D, Effect of imatinib administration on systemic arterial blood pressure of mice, measured by radio
telemetry. Systemic mean arterial blood pressure was measured before (5 minutes) and after (30 minutes) treatment with imatinib 20
mg/kg. NS indicates nonsignificant in a paired t test (n3 mice). E, Analysis of microvascular perfusion of the skin by contrast-
enhanced ultrasonography. The graph shows representative contrast replenishment curves in a single mouse before and after treat-
ment with imatinib 50 mg/kg. The plateau of the replenishment curve represents the microvascular blood volume [A] of the skin. Further
explanation and details of this analysis are provided in the online-only Data Supplement. AU indicates arbitrary units. F, The effect of
imatinib 50 mg/kg on microvascular tissue perfusion of the skin, shown by the microvascular blood volume [A] before (5 minutes) and
after (30 minutes) treatment with imatinib. NS indicates nonsignificant in paired t test (n3 mice).
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Combining in vitro and in vivo measurements of endothelial
barrier dysfunction and vascular leakage, we found that
imatinib protects against edema formation by enforcing the
endothelial barrier. Although edema formation and vascular
leakage may also be affected by changes in blood pressure,
microvascular perfusion, or vascular remodeling, these fac-
tors are less likely to underlie the protective effect of
imatinib. Alteration of blood pressure and microvascular
perfusion as explanation for edema resolution was excluded
in this study, because (1) imatinib did not affect systemic
blood pressure in an experimental set-up similar to the Miles
assay or Kfc measurements, (2) the pressure and the flow in
the pulmonary circulation was kept constant in the Kfc
measurements, and (3) no effects of imatinib on microvascu-
lar perfusion were observed. The acute character of the in
vivo experiments further excludes chronic vascular remodel-
ing as explanation for the protective effects of imatinib on
edema formation and vascular leakage. Therefore, we con-
clude that imatinib protects against edema formation by
preservation of endothelial barrier integrity.
Whereas the Miles assay and the Kfc measurements serve as
proof-of-concept experiments in which imatinib was given as
pretreatment and possible confounders were excluded, the clin-
ical relevance of the protective effect of imatinib on endothelial
barrier function was evaluated in a murine model of sepsis
(CLP). This experiment mimics the clinical setting, because
CLP is considered the most reliable disease model available for
sepsis,17 and because the treatment sequence in this experiment
mimicked the clinical sequence of development of disease and
subsequent initiation of treatment. In septic mice we found that
imatinib reduced vascular leakage of Evans Blue in the kidneys
by 50%, resembling the attenuating effect found in the Miles
assay. In addition, the number of septic mice developing
vascular leakage in the lungs was significantly lower in the
imatinib-treated group than in the vector-treated group. As
reported previously,22 a high interindividual variation was ob-
served for vascular leakage in liver and the lungs, which may
account for the lack of significance in post hoc analyses.
The optimal protective effect of imatinib on endothelial
barrier function was already achieved at concentrations be-
Figure 7. Imatinib attenuates vascular leakage in a murine model of sepsis. A, Study protocol to assess the effect of imatinib on
sepsis-induced vascular leakage of Evans Blue (EB). Sepsis was induced in male C57/BL6J mice by cecal ligation and puncture (CLP).
Vascular leakage of EB was compared between vector- and imatinib-treated mice. Imatinib (50 mg/kg subcutaneous) or vector were
administered 6 hours and 18 hours after induction of sepsis. EB was administered after 23 hours (100 L of 1% EB solution, intrave-
nous), followed by euthanization of the mice at t24 hours. Vascular leakage of EB was measured in the kidneys, the liver, and the
lungs. B, Vascular leakage of EB in the kidneys, corrected for organ dry weight (DW) and the EB plasma concentration. *P0.05,
***P0.001 in Tukey post hoc test of 1-way ANOVA (n5–6 mice per group). C, Vascular leakage of EB in the liver, corrected for organ
dry weight (DW) and the EB plasma concentration. NS indicates nonsignificant, *P0.05 in Tukey post hoc test of 1-way ANOVA
(n5–6 mice per group). D, Vascular leakage of EB in the lungs, corrected for organ dry weight (DW) and the EB plasma concentration.
NS indicates nonsignificant in Tukey post hoc test of 1-way ANOVA (n5–6 mice per group).
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tween 5 and 10 mol/L in vitro. These concentrations
correlate with plasma levels in patients treated with imatinib
for chronic myeloid leukemia23 or gastro-intestinal stromal
tumors.24 Also, the dosage used in our in vivo experiments
resembles imatinib dosages used in the clinical setting. The
slight difference in treatment concentration between our in
vivo experiments (20–50 mg/kg) and clinical treatment dos-
age (5–10 mg/kg) is compensated by the higher metabolism
and the lower half-life of imatinib in mice (T1/22–4 hours in
mice)25 compared with human (T1/218 hours). Therefore,
this study not only explains how imatinib may protect against
edema, but also proposes imatinib administration as promis-
ing approach to edema resulting from endothelial barrier
dysfunction.
Role of Arg in Endothelial Barrier Dysfunction
The protective effects of imatinib on endothelial barrier
function resulted predominantly from inhibition of the non-
receptor tyrosine kinase Arg. Knock-down of Arg mimicked
the effect of imatinib on endothelial barrier function, and
imatinib did not have an additive effect in Arg-depleted cells.
To the best of our knowledge, this is the first report showing
that Arg is involved in endothelial barrier dysfunction. The
importance of Arg as mediator of endothelial barrier dysfunc-
tion was illustrated by the fact that Arg inhibition with
imatinib reduced the thrombin response up to 44%, whereas
the finding that Arg is activated on endothelial stimulation
with the barrier-disruptive agents thrombin, VEGF, and
histamine stresses its relevance.
In search for signaling pathways underlying the barrier-
disruptive actions of Arg, we found that inhibition of Arg by
genetic knock-down or imatinib treatment prevented the loss
of cell–matrix interaction during endothelial stimulation. This
was accompanied by enhanced formation of focal adhesions
(FAs), particularly at the periphery of the cell. As proposed
by Ingber,20 adhesion of cells to the subcellular matrix is one
of the ways for a cell to remain cell shape and counteract
contractile forces during cell retraction. Cell–matrix interac-
tion is mainly achieved through FAs, multifaceted protein
complexes that connect extracellular matrix proteins to the
intracellular cytoskeleton.2 The spatial distribution of FAs is
an important determinant of endothelial barrier function, as
redistribution of FAs to the cell periphery has previously been
associated with improved endothelial barrier integrity.21,26
Fibroblast studies have demonstrated that Arg inhibits this
redistribution by reducing formation and increasing turnover
of peripheral FAs.27 Compared with wild-type, Arg-deficient
fibroblasts show larger and denser FAs, mainly located at the
cell periphery.28 These studies support our finding that Arg
inhibition with imatinib increases the number of FAs at the
cell periphery.
In addition, we found that imatinib enhanced the activity of
Rac1, a GTPase known to enforce both cell–cell interaction1,2
and cell–matrix interaction.2,21 Rac1 activity may enforce endo-
thelial cell–cell junctions via mediators like angiopoietin-1.29
Of note, Rac1 was also described to mediate peripheral
accumulation of FAs, thereby enhancing endothelial barrier
function.21 A direct interrelation between Arg, Rac1, and
integrin-mediated adhesion was recently suggested in a fibro-
blast study that demonstrated that Arg inhibits Rac1 activity
and integrin function.30
Figure 8 shows an overview of the protective effect of
imatinib during endothelial barrier dysfunction as proposed in
this study. Arg is activated upon binding of barrier-disruptive
agents to their receptor. A likely mediator of Arg activation is
Src, a tyrosine kinase that is activated by the thrombin
receptor and the VEGF receptor2 and that is able to bind and
activate Arg.31 Arg activation leads to disassembly of periph-
eral FAs,27,28 thereby reducing cell–matrix interaction. Ima-
tinib inhibits Arg, which directly leads to preservation of
peripheral FAs and improved cell–matrix interaction. In
Figure 8. Overview of the protective effect of imatinib during endothelial barrier dysfunction. Imatinib inhibits Abl-related gene (Arg),
which is activated upon binding of barrier-disruptive agents to their receptor. Arg activation leads to disassembly of peripheral focal
adhesions (FAs) and can be inhibited with imatinib. Peripheral FAs improve cell–matrix interaction and contribute to endothelial barrier
integrity by counteracting contractile forces and supporting cell–cell contacts. In addition, Arg inhibition with imatinib enhances Rac1
activity, which supports both cell–cell contacts and cell–matrix interaction.
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addition, imatinib enhances Rac1 activation, which in turn
improves cell–cell contact and cell–matrix interaction. The
enhanced cell–matrix interaction, by supporting cell–cell
contacts and counteracting contractile forces, limits cell
retraction and gap formation.20
Potential Further Improvement of Endothelial
Barrier Function by Imatinib Derivatives
Considering previous reports on subcutaneous edema as side
effect of imatinib, it is also important to note that in the
concentrations used in this study, imatinib did not affect basal
endothelial barrier integrity. This difference might first of all
be explained by treatment duration. Subcutaneous edema as
side effect may result from chronic PDGFR inhibition (sev-
eral months to years) in pericytes and consequent disturbed
vascular support.32 Second, because c-Abl inhibition impairs
endothelial barrier function33 and imatinib inhibits both Arg
and c-Abl, the protective effect of imatinib may depend on
the balance of Arg and c-Abl expression in a specific vascular
bed. In none of the various macro- and microvascular
endothelial cell types that we tested, c-Abl inhibition with
imatinib impaired barrier function. This suggests that c-Abl
inhibition by imatinib has a limited effect on barrier function.
However, the opposing effects of Arg/PDGFR/c-KIT versus
c-Abl on endothelial barrier function suggest that imatinib-
derivatives lacking c-Abl as target may further improve
treatment of endothelial barrier dysfunction.
Clinical Implications
For several reasons, this study may have direct clinical value.
Imatinib had an optimal protective effect at 10 mol/L, which
correlates with plasma concentrations in patients on imatinib
treatment.23,24 The barrier protective effect observed in our
study was independent of anatomic location, species, endo-
thelial phenotype, and barrier-disruptive agent, indicating a
broad applicability of imatinib. Endothelial barrier protection
was already achieved after short-term treatment (30 minutes
pretreatment in vivo), whereas initiation of imatinib treatment
after induction of sepsis was also shown to be effective. This
may facilitate edema treatment in acute conditions like sepsis,
but also limit side-effects. As noted before, this study
elucidates previous clinical observations favoring imatinib
treatment in edema.5,11 Combining our study with these
clinical observations provides bench-to-bedside evidence for
a protective effect of imatinib on endothelial barrier dysfunc-
tion and supports clinical development of imatinib as thera-
peutic approach to edema.
Conclusion
Thus, imatinib prevents endothelial barrier dysfunction and
edema formation via inhibition of Arg. These findings iden-
tify imatinib treatment as a promising approach to permea-
bility edema and indicate Arg as novel target for edema
treatment.
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CLINICAL PERSPECTIVE
Endothelial barrier dysfunction is a major contributor to morbidity and mortality in the critically ill. Loss of the endothelial
barrier follows exposure of the endothelium to inflammatory mediators and drives vascular leakage and edema formation.
To date endothelial barrier function and vascular leakage still lack appropriate therapy. This study shows that imatinib—an
US Food and Drug Administration–approved tyrosine kinase inhibitor—directly protects the endothelial barrier under
inflammatory conditions. With the use of endothelial cells isolated from various vascular beds, it was shown that imatinib
attenuates the loss of endothelial barrier on stimulation with inflammatory mediators. Imatinib protects against endothelial
barrier dysfunction predominantly by inhibition of the tyrosine kinase Abl-related gene (Arg), a novel mediator of
endothelial barrier disruption. The effect of imatinib on endothelial barrier was established in various mouse models of
vascular leakage. Notably, imatinib attenuated vascular leakage in a murine model of sepsis, even when imatinib treatment
was initiated considerable time after induction of sepsis. This study carries important clinical implications. First, imatinib
may form a suitable therapy for treatment of diseases characterized by vascular leakage. The longstanding experience with
imatinib, together with the fact that imatinib concentrations used in this study parallel plasma values in cancer patients, are
apparent advantages in this case. Logical first steps in further development of imatinib involve Phase I and II trials to
evaluate safety and efficacy of imatinib in patients with profound vascular leakage. Second, the identification of Arg as a
novel and drugable target opens perspectives for more specific pharmaceutical interventions.
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